Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- Semaglutide and other GLP-1 receptor agonists are being studied off-label for psoriasis in patients with obesity or insulin resistance because of their metabolic and anti-inflammatory effects.
- Psoriasis severity often improves when patients lose at least 10% of their body weight, and GLP-1 agonists also act on inflammatory pathways such as IL-17/IL-23 and TNF-α.1
- Current 2026 evidence shows PASI improvements in some patients, although available studies use small groups of patients and relatively short follow-up periods.1
- Paradoxical psoriasis flares can occur but remain uncommon; supervised protocols with lab monitoring help lower risk and support safer use.1
- Patients interested in supervised GLP-1 or GLP-3R therapy for psoriasis can schedule a consultation at Mirror Plastic Surgery for personalized, lab-reviewed care.
- All use of GLP-1 agonists for psoriasis is off-label and should be guided by metabolic comorbidities and coordinated with existing dermatology or rheumatology care.
Ellie Pranckevicius, FNP-BC: Your Peptide and Aesthetics Provider
Ellie Pranckevicius, FNP-BC, leads peptide therapies and non-surgical aesthetics at Mirror Plastic Surgery in St. Petersburg, Florida. She is a board-certified Family Nurse Practitioner with degrees from Boston University and the University of South Florida and four years of experience in the Neuroscience ICU at Tampa General Hospital managing complex metabolic and physiological cases. Her combined esthetician training and advanced clinical nursing background allow her to evaluate both the cosmetic and systemic aspects of inflammatory skin conditions, including psoriasis, within a supervised, lab-guided framework.
Book an appointment with Ellie for a personalized, lab-reviewed assessment of your psoriasis and metabolic health profile.
How GLP-1 Agonists Connect Weight, Inflammation, and PASI Scores
Psoriasis is a chronic immune-mediated skin disease driven by dysregulated Th17/Th23 signaling, elevated TNF-α, IL-17, and IL-23, and systemic low-grade inflammation. The Psoriasis Area and Severity Index (PASI) quantifies disease burden on a 0–72 scale, and a PASI 75 response, meaning a 75% reduction from baseline, is the standard benchmark in clinical trials.
Obesity amplifies psoriatic inflammation because adipose tissue functions as an active immunological organ. It secretes pro-inflammatory adipokines such as leptin and resistin while amplifying the IL-17/IL-23 and TNF-α axes that drive skin disease. Weight loss of at least 10% has been associated with meaningful PASI improvements independent of biologic use, which supports the metabolic-inflammatory link that makes GLP-1 agonists biologically plausible in psoriasis.
GLP-1 receptors are expressed on dendritic cells, macrophages, T-lymphocytes, endothelial cells, and psoriatic skin lesions themselves. This distribution enables both weight-dependent and weight-independent anti-inflammatory effects. GLP-1 signaling suppresses NF-κB–driven cytokine production, reduces macrophage M1 polarization, and attenuates Th17 differentiation, which are pathways central to psoriatic disease.
Current Evidence in 2026: Trials, PASI Outcomes, and Quality of Life
The table below summarizes key 2026 studies and reviews on GLP-1 agonists in psoriasis and related inflammatory conditions.
| Study / Source | Design | PASI Change | Citation |
|---|---|---|---|
| SEMAPSO trial (NCT07401992), 2026 | Phase 4 RCT, n=62, oral semaglutide + topical therapy vs. placebo + topical therapy, 12 weeks | Primary endpoint: SCD-1 activity, key secondary: PASI 75 rate at weeks 4, 8, 12 (results pending) | SEMAPSO trial registry |
| Nicolau et al. prospective cohort, 2025 | 6-month cohort, adults with moderate-to-severe psoriasis and obesity, weekly semaglutide | Clinically meaningful PASI and DLQI improvements alongside weight loss and improved metabolic parameters1 | Practical Dermatology |
| Retrospective semaglutide analysis | Retrospective cohort, psoriasis patients with co-existing obesity | PASI 75 responses reported in some cases1 | RheumNow / NPF primer review |
| BJD 2026 article | Publication on GLP-1 agonists in inflammatory conditions | Variable PASI changes reported across cases | British Journal of Dermatology |
| Pharmaceutics review, Wroclaw Medical University, 2026 | Scientific review of GLP-1 immune modulation | Improvements in psoriasis severity indices following liraglutide or semaglutide in patients with obesity or type 2 diabetes1 | EurekAlert / Pharmaceutics |
Available evidence uses relatively small patient groups and short follow-up periods, and study designs vary. Most data come from patients with obesity or type 2 diabetes. The SEMAPSO trial currently represents the most rigorous prospective test of oral semaglutide in psoriasis.
Semaglutide, Psoriatic Arthritis, and Real-World Use Cases
Psoriatic arthritis shares these same inflammatory pathways and the metabolic burden of obesity worsens joint outcomes. Ideal candidates for GLP-1 receptor agonists in psoriasis are patients with BMI of at least 30, or at least 27 with comorbidity, particularly those with obesity or overweight plus metabolic syndrome, type 2 diabetes, established cardiovascular disease, or MASH.
Real-world patient scenarios where GLP-1 adjunct therapy is most clinically relevant include:
- Adults with moderate-to-severe plaque psoriasis and BMI of at least 30 who have had suboptimal responses to topical or conventional systemic therapies
- Patients with psoriatic arthritis and insulin resistance or type 2 diabetes seeking cardiometabolic risk reduction alongside skin and joint management
- Biologic-naïve obese psoriasis patients, who appear to derive the greatest additive benefit from GLP-1 receptor agonists
- Patients already on IL-17 or IL-23 inhibitors who have residual metabolic disease burden and want adjunct weight management
Book an appointment with Ellie to discuss whether a supervised GLP-1 or GLP-3R protocol fits your psoriasis and metabolic profile.
Ozempic, Psoriasis, and Paradoxical Flares: Risk and Monitoring
Paradoxical psoriasis flares after starting a GLP-1 receptor agonist appear in case reports. A 2026 JAAD Case Reports article described a psoriasis flare after tirzepatide initiation in a patient with plaque psoriasis in remission, which ultimately required escalation to ixekizumab for clearance. Earlier reports have linked psoriatic exacerbation to liraglutide and exenatide as well.
A 2024 cross-sectional analysis of FDA adverse event reports found that liraglutide was the GLP-1 receptor agonist most frequently associated with dermatologic adverse events, followed by semaglutide and tirzepatide, with reactions including rash, pruritus, alopecia, and bullous pemphigoid. These reports do not prove causality or frequency but highlight the value of structured monitoring.
Key safety and monitoring considerations for GLP-1 use in psoriasis patients include:
- Class-wide contraindications: personal or family history of medullary thyroid carcinoma or MEN2, active or prior pancreatitis, and severe gastroparesis
- Gastrointestinal adverse effects: nausea, vomiting, diarrhea, and constipation are common and usually transient during dose titration
- Baseline labs recommended in practice: renal function, hepatic function, HbA1c, lipid panel, and baseline ALT
- Psoriasis-specific monitoring: regular checks of psoriasis severity, quality of life, weight, blood pressure, cardiovascular risk, and GI tolerance
- Hair thinning: often telogen effluvium triggered by rapid weight loss, sometimes worsened by reduced protein and micronutrient intake
- Muscle mass: resistance exercise during therapy is advised to help offset lean mass loss with rapid weight reduction
Why Mirror Plastic Surgery’s Supervised Protocols Differ from Online Peptides
The unregulated online peptide market carries significant risks, including lack of third-party batch testing, unknown active ingredient concentrations, and no clinical oversight to screen for contraindications or drug interactions. Prescribing decisions for semaglutide and other GLP-1 receptor agonists in patients with psoriasis should be driven by comorbid metabolic indications and include adverse-event surveillance, a standard that unsupervised sourcing cannot meet.
Mirror Plastic Surgery’s supervised protocol offers several safeguards and support features:
- Comprehensive 30–60 minute consultation with Ellie Pranckevicius reviewing full medical history, current medications, and psoriasis history
- In-depth lab panels covering thyroid, liver, kidney, diabetes markers, and hormone profiles before starting any protocol
- Peptides sourced from reputable compounding providers with rigorous batch testing for purity and accurate dosage
- Ongoing concierge support through direct text access to Ellie, with telemedicine availability across the United States
- Protocol adjustments based on lab follow-up and clinical response, including PASI tracking and metabolic marker reassessment
GLP-3R Compounding: Newer-Generation Option with Improved Tolerability
Mirror Plastic Surgery offers GLP-3R compounding as a newer-generation alternative to first-generation GLP-1 agonists. GLP-3R formulations are reported to have a lower gastrointestinal side-effect burden than older GLP-1 agents, are less likely to cause muscle wasting, and support broader indications including insulin resistance, weight management, and cardiovascular risk reduction. For psoriasis patients who have stopped semaglutide or liraglutide because of GI intolerance, GLP-3R can provide a clinically relevant option within a supervised protocol.
Dual GIP/GLP-1 agonists such as tirzepatide are considered biologically plausible adjuncts for psoriasis because of their mean weight-loss efficacy of approximately 16% versus placebo in non-diabetic patients with obesity. The GLP-3R class builds on this mechanistic rationale while aiming for an improved tolerability profile.
Coordinating GLP-1 Therapy with Dermatology and Rheumatology Care
Rheumatologists and dermatologists are encouraged to co-manage appropriate patients receiving GLP-1 receptor agonists for psoriasis. GLP-1 receptor agonists can be coadministered with methotrexate, cyclosporine, and biologic therapies without clinically meaningful pharmacokinetic interactions, which makes combination approaches feasible.
The American Academy of Dermatology advises patients starting GLP-1 therapy to consult a dermatologist beforehand for baseline assessment of hair, skin, and nail conditions and to consider slower titration and daily multivitamin use. Mirror Plastic Surgery’s concierge model supports this coordination, and Ellie’s clinical background allows her to communicate directly with a patient’s dermatologist or rheumatologist as part of an integrated care plan.
Book an appointment with Ellie to explore how a supervised GLP-1 or GLP-3R protocol can complement your existing dermatology or rheumatology care.
Frequently Asked Questions
Can GLP-1 medications make psoriasis worse?
GLP-1 receptor agonists can, in some cases, trigger paradoxical psoriasis flares.1 Case reports describe new or worsening psoriatic eruptions after starting tirzepatide, liraglutide, and exenatide. These events appear uncommon compared with the overall number of people using these medications, and causality has not been definitively proven. Clinical literature more often reports improvement in psoriasis severity, especially in patients with obesity or metabolic comorbidities.1 Structured monitoring, including baseline PASI scoring and regular follow-up, provides an appropriate safeguard. Patients with a history of psoriasis should share this information with their provider before starting any GLP-1 therapy.
What is the best GLP-1 for psoriasis?
No GLP-1 receptor agonist is FDA-approved for psoriasis, so no agent holds a regulatory designation as best for this indication. The strongest published evidence for psoriasis improvement exists for semaglutide and liraglutide, with semaglutide showing PASI 75 responses in some retrospective cohorts and clinically meaningful PASI and DLQI improvements in a six-month prospective cohort. Tirzepatide has demonstrated significant skin clearance benefits when added to ixekizumab in a 2026 phase 3b RCT, although psoriasis-specific data for tirzepatide as monotherapy remain limited.1
Newer GLP-3R formulations offer an improved tolerability profile and are available through supervised compounding protocols at Mirror Plastic Surgery. The most appropriate agent depends on an individual’s metabolic comorbidities, GI tolerance, current medications, and lab findings, which Ellie Pranckevicius reviews during a comprehensive consultation.
Can Ozempic cause a psoriasis flare-up?
Ozempic (semaglutide) appears in FDA adverse event reporting data for dermatologic reactions, although less often than liraglutide. Published case literature documents psoriasiform exacerbations with GLP-1 class agents, and semaglutide cannot be fully excluded as a potential trigger in susceptible individuals. The mechanism remains unclear, with hypotheses including immune modulation unrelated to weight loss or a rebound inflammatory response during rapid metabolic change. Patients with pre-existing psoriasis who are considering semaglutide should undergo baseline skin assessment, disclose their psoriasis history and current treatments, and have a monitoring plan in place before starting therapy.
Is semaglutide safe to use alongside biologic psoriasis treatments?
Available evidence indicates that semaglutide and other GLP-1 receptor agonists do not cause immunosuppression and do not add meaningful infectious risk in patients already receiving biologic therapies such as IL-17 or IL-23 inhibitors. No clinically meaningful pharmacokinetic interactions have been identified between GLP-1 receptor agonists and methotrexate, cyclosporine, or approved biologic agents for psoriasis. A 2026 phase 3b RCT showed that adding tirzepatide to ixekizumab produced higher PASI 100 rates than ixekizumab alone, with no new safety signals identified, although gastrointestinal adverse events were more frequent in the combination arm. Medical supervision, including lab monitoring and coordination with the prescribing dermatologist or rheumatologist, remains essential when combining these therapies.
Required Disclaimers
The information in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Semaglutide, tirzepatide, liraglutide, and related GLP-1 receptor agonists are not FDA-approved for the treatment of psoriasis. GLP-3R compounding peptides are not FDA-regulated. All peptide and GLP-1 protocols at Mirror Plastic Surgery are provided under the clinical supervision of Ellie Pranckevicius, FNP-BC, following individualized consultation and, when appropriate, laboratory assessment. Patients should consult their dermatologist, rheumatologist, or primary care provider before starting or changing any treatment for psoriasis or metabolic conditions. Individual results vary. Mirror Plastic Surgery is located at 780 4th Ave S, St. Petersburg, FL 33701. Phone: 727-361-6515.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
